Silveira, Elaine; Cavalcante, Isadora Pontes; Kremer, Jean Lucas; Mendonça, Pedro Omori Ribeiro de; Lotfi, Claudimara Ferini Pacicco 
Fonte: Cancer Cell International. Unidade: ICB
Assuntos: CARCINOMA, QUIMIOTERÁPICOS, NEOPLASIAS DO CÓRTEX SUPRARRENAL, CÓRTEX ADRENAL, CITOTOXINAS, FÁRMACOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SILVEIRA, Elaine et al. The tyrosine kinase inhibitor nilotinib is more efficient than mitotane in decreasing cell viability in spheroids prepared from adrenocortical carcinoma cells. Cancer Cell International, v. 18, p. 16 , 2018Tradução . . Disponível em: https://doi.org/10.1186/s12935-018-0527-x. Acesso em: 10 nov. 2024.APA
Silveira, E., Cavalcante, I. P., Kremer, J. L., Mendonça, P. O. R. de, & Lotfi, C. F. P. (2018). The tyrosine kinase inhibitor nilotinib is more efficient than mitotane in decreasing cell viability in spheroids prepared from adrenocortical carcinoma cells. Cancer Cell International, 18, 16 . doi:10.1186/s12935-018-0527-xNLM
Silveira E, Cavalcante IP, Kremer JL, Mendonça POR de, Lotfi CFP. The tyrosine kinase inhibitor nilotinib is more efficient than mitotane in decreasing cell viability in spheroids prepared from adrenocortical carcinoma cells [Internet]. Cancer Cell International. 2018 ;18 16 .[citado 2024 nov. 10 ] Available from: https://doi.org/10.1186/s12935-018-0527-xVancouver
Silveira E, Cavalcante IP, Kremer JL, Mendonça POR de, Lotfi CFP. The tyrosine kinase inhibitor nilotinib is more efficient than mitotane in decreasing cell viability in spheroids prepared from adrenocortical carcinoma cells [Internet]. Cancer Cell International. 2018 ;18 16 .[citado 2024 nov. 10 ] Available from: https://doi.org/10.1186/s12935-018-0527-x
